CoChat

The lessons of Vioxx—drug safety and sales

Open access
Waxman, Henry A. · 2005 · New England Journal of Medicine

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

In May, the Government Reform Committee of the U.S. House of Representatives held a hearing that explored how drugs with serious safety issues can remain so popular for so long. Representative Henry Waxman describes how what was learned illuminated the practices that pharmaceutical manufacturers use to promote their products to physicians.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmp058136

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

See all 99

Metadata

Authors
Waxman, H. A.
Corresponding author
Waxman, Henry A.
Venue
New England Journal of Medicine
Published
2005-06-23
Volume
352
Issue
25
Pages
2576-2578
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1994883059
Cited by
99
References
2
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 1 · 2013: 3 · 2012: 7
FWCI
7.91
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • DigitalGeorgetown (Georgetown University Library) (submittedVersion)
Topics
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
rofecoxib, drug safety, pharmaceutical marketing, pharmaceutical industry, drug approval, adverse drug reactions, congressional hearings
MeSH terms
Anti-Inflammatory Agents, Non-Steroidal, Arthritis, Drug Evaluation, Drug Industry, Gastrointestinal Diseases, Humans, Lactones, Myocardial Infarction, Naproxen, Sulfones, United States, Scientific Misconduct, Cyclooxygenase Inhibitors, Marketing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.